Objectives: Infections caused by Klebsiella pneumoniae (Kp) carbapenemase (KPC)-producing strains of Kp have become a significant threat in recent years. To assess their outcomes and identify risk factors for 14 day mortality, we conducted a 4 year (2010-13) retrospective cohort study in five large Italian teaching hospitals.
Introduction
The production of Klebsiella pneumoniae (Kp) carbapenemases (KPCs) by Kp isolates has become a significant problem in recent years, both from epidemiological and clinical points of view. Substantial percentages of hospitalized patients are colonized by these microorganisms, which have caused several outbreaks of severe nosocomial infections, including bacteraemia and ventilator-associated pneumonia, since 2010. In some countries, KPC-producing Kp isolates (KPC-Kp) are now considered endemic. 1 -12 Reported rates of mortality associated with KPC-Kp infections vary widely from 22% to 72%. 5,8,9,13 -15 The variability depends largely on differences involving the populations analysed in the various studies, including those related to age and underlying disease/comorbidity profiles. It also could reflect the potential inclusion of patients with KPC-Kp colonization rather than true infections, which can obviously distort assessment of treatment success and case outcomes. For clinicians, selecting an effective treatment regimen for KPC-Kp infections is a major challenge. Nonetheless, published data suggest that survival benefits might be associated with regimens that include two or more drugs that display activity against the isolate and paradoxically the most pronounced improvement seems to be produced by combination regimens that include a carbapenem. 4, 5, 14, 15 A randomized trial with more in-depth analysis of clinical characteristics and outcomes is needed to define the best antimicrobial regimen for management of these infections. In the meantime, we conducted a large multicentre retrospective study aimed at pinpointing risk factors for KPC-Kp infection-related mortality in subgroups of patients with different clinical and epidemiological profiles, with emphasis on factors related to antimicrobial drug therapy.
Methods

Study design, setting and patients
A retrospective cohort study was conducted between 1 January 2010 and 31 December 2013 in five large academic healthcare facilities in Italy. The cohort consisted of patients aged ≥18 years, who had been consecutively admitted to the facility during the study period and had developed a culture-confirmed infection caused by a KPC-Kp strain. A proportion of the patients included in this study (451/661, 68%) have been reported in previous articles from our group. 5, 11, 12 Patients were classified as having KPC-Kp bloodstream infections (BSIs) if they had blood culture positivity for a KPC-Kp strain and clinical signs of systemic inflammatory response syndrome. 16 BSIs were further classified as low risk or high risk depending on the source of the bacteraemia (urinary tract versus all other identified and unidentified sources, respectively). 17 The criteria for classification as a non-bacteraemic KPC-Kp infection were: (i) documented recovery of a KPC-Kp isolate from cultures of intra-abdominal wounds, urine, respiratory tract specimens (sputum or bronchoalveolar lavage fluid) or other sites; (ii) no blood culture positivity for KPC-Kp for the duration of hospitalization; (iii) clinical signs of infection; 18 and (iv) post-antibiogram treatment with an antimicrobial regimen that was consistent with the isolate's in vitro susceptibility profile. Two infectious diseases specialists independently reviewed data available at the time of each patient's discharge or death to exclude cases representing KPC-Kp colonization rather than infection. The Research Ethics Committee of the coordinating centre (Catholic University of the Sacred Heart) approved the study and informed consent was waived because of the retrospective observational nature of the study.
Microbiology, KPC gene identification and antimicrobial susceptibility testing
The Vitek 2 system (bioMérieux, Marcy l'Étoile, France) was used in all participating centres for isolate identification and antimicrobial susceptibility testing. Vitek MICs were classified according to EUCAST breakpoints. 19 The presence of carbapenemase genes of bla KPC , bla NDM , bla VIM and bla OXA-48 types was investigated by PCR and DNA sequencing analysis using the protocol described by Endimiani et al.
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Definitions
The following terms were defined prior to data analysis. Hospital admission was defined as the date the patient was admitted to the study facility. Infection onset was defined as the collection date of the index culture (i.e. the first culture that yielded the study isolate). Septic shock was defined as sepsis associated with organ dysfunction and persistent hypotension despite volume replacement. 21 Infections were considered hospital acquired, healthcare associated or community acquired as defined by the ECDC. 22 An empirical antimicrobial treatment regimen was defined as inadequate unless it included at least one drug displaying in vitro activity against the KPC-Kp isolate. Regimens were classified as monotherapy or combination therapy depending on the number of active drugs they included.
Variables explored as possible predictors of mortality
The primary outcome measured was death within 14 days of infection onset. In-hospital mortality was assessed as a secondary outcome. Survivor and non-survivor subgroups were compared in order to identify predictors of 14 day mortality. The variables considered are listed in Table 1 . Comorbidities were also collectively expressed on the basis of the Charlson index 23 and severity of illness was expressed by the APACHE III score. 24 
Statistical analysis
The results are expressed as the mean+SD or median (IQR) (continuous variables) or as percentages of the group from which they were derived (categorical variables). Student's t-test and the Mann -Whitney U-test were used to compare normally and non-normally distributed continuous variables, respectively. Categorical variables were evaluated with the x 2 or twotailed Fisher's exact test. ORs and 95% CIs were calculated for all associations that emerged. Two-tailed tests were used to determine statistical significance; a P value of ,0.05 was considered significant. Multivariate logistic regression analysis was used to identify independent risk factors for 14 day mortality. Variables emerging from univariate analysis with P values of ,0.1 were included in the multivariate model in a backward stepwise manner. The discriminating ability of the model was assessed by estimating the area under the receiver operating characteristic (ROC) curve. Collinearity was assessed by generating a correlation coefficient matrix. A propensity score for receiving combination therapy was added to the model, in order to provide a means of balancing baseline covariates predictive of treatment, mitigating the unequal chance of receiving monotherapy versus combination therapy and to control for confounding. The propensity score was calculated using a bivariate logistic regression model in which the outcome variable was use of combination therapy. All statistical analyses were performed with the Intercooled Stata program (version 11). Figure 1 reports the flow chart of the patient inclusion process. The characteristics of the 661 patients who met the criteria for inclusion in our study are shown in . During the study period, rates of non-susceptibility to each of these drugs increased alarmingly among study isolates: from 6% (gentamicin), 11% (colistin) and 9% (tigecycline) in 2010 to 21%, 27% and 25%, respectively, in 2013.
Results
Antimicrobial treatment
All patients were empirically treated with currently standard doses of drugs with known Gram-negative activity (alone or with other antibiotics). Over half (365/661, 55.2%) proved to be inadequate in light of in vitro susceptibility data. Single-drug regimens (colistin in 121 patients, tigecycline in 116 and gentamicin in the remaining 70) were prescribed for 307/661 (46.4%) patients. As shown in Table 1 , most patients (354/661, 53.5%) received two or more drugs with in vitro activity against the KPC-Kp isolate. Most combinations included at least one carbapenem (meropenem in all cases; meropenem and ertapenem in 8) and in 12 cases the regimen also included rifampicin. In Table 2 , characteristics of patients according to treatment with mono-or combination therapy are reported. Colistin, gentamicin, tigecycline and meropenem in definitive regimens were administered as previously reported. 5 
Outcomes of infections
Most deaths occurred within 14 days after KPC-Kp infection onset (225/661 patients, 34.1%) while the in-hospital mortality rate was 41.1% (272/661 patients). As shown in Table 3 , a significantly higher 14 day mortality rate was observed in the BSI subgroup Mortality related to KPC-producing Klebsiella pneumoniae 2135 JAC Mortality related to KPC-producing Klebsiella pneumoniae of those who were on combination regimens (P ¼ 0.03). The protective effects of combination therapy were highly significant in the most critically ill patients of the cohort (those in the ICU, those with APACHE III scores ≥15 and those whose infections presented with septic shock) and those who had received inadequate empirical therapy. The association between 14 day survival and combination therapy was also strong among patients with BSIs, excluding those classified as low-risk infections. In patients with non-bacteraemic KPC-Kp infections, the positive impact of combination therapy on survival was significant only in the subgroup with lower respiratory tract infections. Figures 2 and 3 show the 14 day mortality rates associated with more-specific antimicrobial drug regimen categories. For patients whose combination regimens included meropenem, Tumbarello et al.
14 day mortality rates were significantly lower than those associated with monotherapy only when the meropenem MICs for the KPC-Kp isolates were ≤8 mg/L.
Predictors of mortality
Univariate analysis revealed significant differences between the 14 day outcome-based subgroups ( Table 4 ). As shown in Table 5 , BSI, septic shock at infection onset, inadequate empirical antimicrobial therapy, chronic renal failure, high APACHE III score and colistin-resistant isolates emerged as independent predictors of 14 day mortality. Post-antibiogram combination therapy was associated with a lower risk of mortality. The model had an area under the ROC curve of 0.79, indicating good predictive ability, and absence of multicollinearity. After adjustment for the propensity score in the logistic regression model evaluating risk factors for mortality, treatment with combination therapy showed an OR of 0.64 (95% CI, 0.45 -0.90; P ¼ 0.01).
Discussion
Our findings in the 661 patient cohort described above-the largest sample of patients with infections caused KPC-Kp analysed to date-confirm the high mortality associated with these infections in previous studies. 5, 15, 25, 26 Deaths were significantly more common in patients with BSIs or lower respiratory tract infections than in those with infections at other sites. This finding probably reflects the severity of these infections and/or the relatively poor overall condition of the patients who contract them. This conclusion is supported by the fact that mortality in our cohort was independently predicted by septic shock and high APACHE III score at infection onset and it is also in line with previous reports. As for the non-empirical phase of treatment, our findings confirm previous reports on the mortality-limiting effects of regimens containing two or more drugs with activity against the isolate. 4,5,8,15,27 -29 A more detailed analysis of this protective effect revealed that, in general, the benefits of multidrug therapy are more pronounced in patients who are critically ill. These findings are consistent with those that recently emerged from a smaller study that was limited to patients with KPC-Kp BSIs. 15 The impact on survival of combination drug therapy also varied within the subset of KPC-Kp BSIs: in most cases the mortality risk reduction was quite strong, but the benefits declined (and became statistically non-significant) when the urinary tract was the source of the BSI. This finding tends to support the view that combination therapy is particularly important for clinically severe infections caused by KPC-Kp.
In several studies, drug combinations that included carbapenems have performed better than other multidrug regimens, leading some groups to suggest that carbapenems are an important component in the treatment of KPC-Kp infections, especially BSIs. 5, 14, 15 This assertion is somewhat surprising since KPC enzymes hydrolyse carbapenems. Data from the present study indicate that the favourable impact on survival of active drug combinations that include at least one carbapenem is significant only when the meropenem MIC for the KPC-Kp isolate is ≤8 mg/L. Identical results have recently been reported by Daikos et al., 15 who noted that their findings were also consistent with the human pharmacokinetic/pharmacodynamic data they had previously reviewed. 9 Possible explanations for this observation may be found in in vitro/in vivo animal model studies, which showed that carbapenems, alone or combined with different drugs commonly Tumbarello et al. 32, 33 A problem of considerable importance is the increasing rate of colistin resistance among Kp isolates. In vitro resistance to this drug was an independent predictor of 14 day mortality in our cohort and similar findings have been reported by others in patients with carbapenem-resistant Kp infections. 34 It is worth noting that during the 4 year period covered by our study, the percentage of KPC-Kp isolates displaying colistin resistance almost tripled.
The presence of chronic renal failure also emerged as an important predictor of 14 day mortality, probably because it reduced the therapeutic options. Drugs with potential renal toxicity (colistin or gentamicin, especially when combined with other agents) would have to be avoided and less toxic-and also less effective-single-drug regimens prescribed. This finding is consistent with recently reported data on patients with carbapenem-resistant Kp infections treated with polymyxin B monotherapy: in this population, baseline renal insufficiency was associated with a 6.0-fold increase in clinical failure after adjustment for the presence of septic shock. 35 Our study has certain limitations that must be acknowledged. Firstly, the nature of our analysis was retrospective. Secondly, our study was performed in a country with a high prevalence of KPC-Kp, therefore the results may not be necessarily applicable to other settings different from ours. Thirdly, it is possible that there may have been some degree of misclassification as infection (instead of colonization) cases among non-bacteraemic patients. Fourthly, but not less importantly, despite the large population sample included, the present is an observational study and not a clinical trial; therefore, of course, our data and conclusions cannot represent therapeutic recommendations for clinicians.
In conclusion, this large multicentre cohort study shows that infections caused by Kp strains expressing KPC-2 or KPC-3 enzymes are associated with a high mortality rate. Our findings confirm the survival benefits of non-empirical regimens that include two or three active drugs (as compared with active monotherapy) and indicate that the most significant reduction in mortality is seen in patients with more severely compromised clinical conditions. Combination regimens that include meropenem can provide appreciable therapeutic benefits if the meropenem MIC for the KPC-Kp isolate is ≤8 mg/L, but no benefits are likely when the meropenem MIC exceeds 32 mg/L. Further study is needed to define the potential value of carbapenem-containing combinations for isolates with intermediate meropenem MICs, including those as high as 16 mg/L. Tumbarello et al.
